Few, but Efficient: The Role of Mast Cells in Breast Cancer and Other Solid Tumors Open Access

Mast cells (MC) belong to the innate arm of the immune system, they derive from CD34⁺ CD117⁺ pluripotent hematopoietic stem cells within the bone marrow (BM) and complete their differentiation in tissues (1). On the basis of their role, MCs are differentially located in human tissues although they are predominantly abundant in close proximity to vessels (2), epithelia, fibroblasts (3), and nerves (4). MCs store many small secretory granules, whose content allows the classification of MCs in two major types: MC_(T) and MC_(TC). The former are characterized by granules that are particularly rich in tryptase, they play mainly a role in the immune response and can be found near the external mucosa of the gastrointestinal and respiratory apparatuses (5, 6). Conversely, MC_(TC) display secretory granules with tryptase together with chymase and carboxypeptidase, contribute to tissue repair and are sited in the submucosa and connective tissues in close proximity to blood and lymphatic vessels (6). The specific signals responsible for progenitor recruitment and the mechanisms underlying MC differentiation are still poorly understood. MC biology is often studied by employing mouse models, although MC features are not fully conserved between human and mice (7). Hence, in this review, we will indicate whether findings were obtained in mouse models.

MC function is well characterized in allergic reactions and parasite responses, but their role in cancer is less understood and it is still a matter of debate. MCs can be detected both at the margins or infiltrating the tumor and have been reported to be endowed with both protumor or antitumor (8) properties depending on their abundance and localization, the type of stimuli and tumor context. Upon activation, MCs release a wide range of soluble mediators with either proinflammatory (e.g., TNF) or anti-inflammatory (including IL10 and TGFβ) effects (9). Moreover, MCs can differentially promote an inflammatory or immunosuppressive tumor microenvironment (TME) by modulating the functions of diverse immune populations (10), such as CD8⁺ T cells (11). Moreover, in mouse models, MCs have been shown to regulate myeloid-derived suppressor cells (MDSC; ref. 12), tumor-associated macrophages (13), and regulatory T cells (Treg; ref. 14). MCs can sense environmental modifications and influence stromal (15) and immune components of the TME (16) in a bidirectional cross-talk, which enables them to finely tune the host responses in the presence of developing tumors, ultimately influencing their outcome (17).

MC presence has been shown to be associated with poor prognosis and aggressive disease in diverse cancer types including Hodgkin lymphoma (18), pancreatic adenocarcinoma (19, 20), hepatocellular carcinoma (HCC, ref. 21), and cholangiocarcinoma (22). In patients with Hodgkin lymphoma, MC infiltration is predictive of worse relapse-free survival rates (18). The same effect has been reported in pancreatic cancers, where presence of tumor-infiltrating MCs is associated with higher grade and reduced survival. Notably, through in vitro experiments, it was shown that pancreatic tumor cells could promote MC infiltration, which, in turn, favors cancer cell growth and invasion, and in this manner worsens the outcome of the disease (20). MC number also increases along with carcinogenesis in HCC and intrahepatic cholangiocarcinoma (21). In these tumors, MCs could promote cancer fibrosis and immune response, negatively affecting patients' survival rate. In cholangiocarcinoma, a vicious circle has been described between cholangiocytes and MCs. By employing both in vitro and mouse models, it was proposed that MC-derived histamine promotes cholangiocyte proliferation, thus favoring cholangiocarcinoma progression and angiogenesis. Simultaneously, cholangiocytes secrete stem cell factor (SCF), which stimulates MCs via c-Kit (23).

In other types of tumors, MC role is less clear and could depend on their localization. This is the case of colorectal cancer where MC infiltration has been defined as a favorable independent prognostic factor (24), although the presence of a high number of MCs localized in the peritumoral is associated with poor prognosis (19, 25). Moreover, MCs were shown to be crucial for the development of preneoplastic polyps. In fact, it was reported that MCs are enriched in the polyp masses of patients and, at least in mouse models, are necessary to transform premalignant lesions in colon cancer (26). Also in prostate cancer preclinical models, MCs display a different effect depending on their tissue compartment localization (27). Intratumor MCs inhibit angiogenesis and tumor growth, whilst peritumor MCs promote the expansion of human prostate tumors. During the onset of castrate-resistant prostate tumors, MCs are mobilized to the peritumoral area where they contribute to tumor relapse (27). Hence, their inhibition could be exploited to enhance the effects of castration in this setting. In melanoma, MCs have been associated with better patients' survival (28), but also with poor prognosis (29) and resistance to immune therapy (30) as shown in patients and through mouse models. In breast carcinomas, the comprehension of the role of MCs is made even more complicated by the high intertumor and intratumor heterogeneity and by the diverse outcomes, which characterize the different breast carcinoma subtypes (31).

Breast carcinoma is currently the most common type of tumor in women with about 2 million new cases every year (32). Breast carcinoma is a highly heterogeneous disease in terms of phenotypical features and tumor aggressiveness, making patients’ outcome and response to therapy extremely variable (33). In the clinical practice, treatment decision is commonly based on histopathologic markers that is, expression of hormone receptors (HR), HER2, and Ki67, which define different breast carcinoma subtypes: luminal A and B, HER2-positive, and triple-negative (TN) breast carcinomas. Luminal breast carcinomas are usually characterized by better prognosis, while HER2-positive breast carcinomas and TNBCs show a more aggressive behavior and unfavorable prognosis (34). The efficacy of the treatment is not only influenced by the expression levels of these receptors, but also by the quality and quantity of immune infiltrate (35).

Recently, numerous studies have employed CIBERSORT (36) to infer the proportions of 22 immune cell subsets and evaluate the association between the abundance of the diverse immune subpopulations and the clinical outcome of solid tumors (37). CIBERSORT was employed to analyze the gene expression profiles of almost 11,000 tumors and verify whether differences in the immune infiltrate depend on the molecular subtype (38). This work allowed to evaluate the effect of innate immunity in cancer since, until then, the association between immune infiltration and clinical outcome was generally limited to adaptive immunity. Moreover, results confirmed the complexity between MC infiltration, cancer cell molecular profiles and clinical features.

Other studies aimed at determining whether specific molecular profiles of breast carcinomas are characterized by a different density of infiltrating MCs (39–42). MC abundance has been compared between highly HR-positive (>50%) cancers versus tumors with low expression of HRs (<5%; ref. 41) finding an increased number of MCs (detected by Giemsa and Alcian blue staining) in the former group, mainly in the peritumoral zone. Glajcar and coworkers investigated the density of tryptase- and chymase-expressing MCs in different molecular subtypes of breast carcinoma, according to the molecular classification of St Gallen 2013 International Expert Consensus (43), to evaluate their association with standard prognostic markers (39). This study showed that low- and intermediate-grade breast carcinomas are characterized by high density of MCs both infiltrating the tumor and at the invasive margins. A statistically significant higher presence of both chymase- and tryptase-positive MCs was observed in luminal (estrogen or progesterone receptor positive; ER⁺ or PR⁺) compared with non-luminal (ER⁻ and PR⁻) tumors (Fig. 1). The in silico analysis of gene expression profiles of the molecular taxonomy of breast carcinoma international consortium (METABRIC) database through CIBERSORT algorithm (36) confirmed that there is a significantly higher infiltration of MCs in luminal tumors, particularly luminal A, compared with more aggressive HER2-positive and TNBC subtypes (40).

Immune infiltrate is differently associated with survival probability (44) based on the expression of HRs. Because MCs are more abundant in HR-positive breast carcinoma tumors, which are characterized by a better prognosis, it has been hypothesized that MCs could be endowed with a favorable prognostic value (Table 1). Accordingly, MCs are negatively associated with the proliferation rate, identified by a lower expression of Ki67 (39). The positive correlation between MC presence and expression of ER, or the ER-target gene BCL2, was confirmed also showing a negative correlation of MCs with the TNBC marker EGFR (45). In accordance to this, we found that in vitro MCs reduce the activation of EGFR and cMET receptors (40), which are both regulators of the basal program and are highly expressed in TNBCs. MCs were shown to inhibit cMET also by cleaving its ligand, HGF, into an NK4-like inhibitory molecule (46). Altogether these findings support the hypothesis that MCs could not only be recruited more efficiently by ER-positive breast carcinoma cells, but could also promote their luminal phenotype by favoring the expression and activity of ER, while simultaneously inhibiting the function of basal receptors such as cMET and EGFR (Fig. 1). In preclinical settings, MC presence has been associated to increased aggressiveness in luminal B models. In fact, breast carcinoma growth and metastasis formation were increased in a C57BL/6 MMTV-PyMT mouse model, when compared with C57BL/6-Kit^W-sh/W-sh (Wsh) mice, which lack MCs due to an inversion of the c-Kit promoter (47).

In HR-positive luminal tumors, the expression of ER is obviously a positive predictive marker of responsiveness to hormonal-based interventions, but recent data from neoadiuvant studies suggest that ER status displays an opposite effect in patients with HER2-positive breast carcinoma treated with anti-HER2 therapy (48, 49). Trastuzumab, the standard of care for the treatment of HER2-positive breast carcinomas (34), is often effective in combination with chemotherapy, but some patients do not respond and eventually progress (50). To overcome resistance to trastuzumab, several novel HER2-targeting agents have been developed, including the tyrosine kinase inhibitor (TKI) lapatinib, and the mAb pertuzumab (51). However, ER activation could represent an escape pathway that promotes cell survival and resistance to therapy (52, 53). Because ER expression hampers the efficacy of anti–HER2-based therapy and given the capacity of MCs to increase ER level and activity (40), MCs may negatively affect the response to anti-HER2 therapy also via ER stimulation. The analysis of breast carcinoma transcriptomes confirmed that the presence of a high fraction of MCs correlates with worse disease-free survival (DFS) (54) and overall survival (OS). These observations have been confirmed by independent works that highlighted a negative effect of MCs in HER2-positive breast carcinoma patients’ outcome (38, 54, 55). Patients treated with trastuzumab and displaying a high risk of relapse [trastuzumab risk model (TRAR)-high] (56) express higher levels of genes associated to MCs. Furthermore, the MC-related gene carboxypeptidase A (CPA3) correlates with ER expression (ESR1) and ER-activated genes, for example, PGR, BCL2, and SCUBE2, unveiling a novel possible link between MCs and clinical resistance to trastuzumab therapy (40).

In contrast with data obtained from HER2-positive tumors, Bense and colleagues reported that activated MCs are associated with a higher pathologic complete response (pCR) rate in TNBC patients, thus supporting the role of MCs as favorable predictive markers in this breast carcinoma histotype (54). It has been shown that MCs are recruited by tumors, and TNBC cells then stimulate their activation and degranulation (57). In this scenario, activated MCs appear to mold a tumor stroma characterized by antitumor rather than supportive features (57). In accordance to the potential positive prognostic value of MCs in breast carcinomas, other studies depict the possible association between MC infiltrates and low tumor grade (41, 45, 58). The presence of MCs in the peritumoral stroma improves the prognosis of breast carcinomas with long-term follow-up, particularly in the node-negative subset, supporting an important biological role for MCs in mammary tumors (58). Moreover, the value of MC presence as an independent prognostic factor of good prognosis in invasive breast carcinomas was validated in a large tissue microarray study of 4,444 cases (45). Herein, Kaplan–Meier survival curves showed that MC presence is a favorable prognostic marker in the entire set of analyzed invasive breast carcinomas. Conversely, Okano and colleagues described an association between Annexin A1, a protein that has been reported in various studies to be predictive of a significantly shorter OS in patients with TNBC (59), with MCs. Here, MCs have also been linked with various aggressive phenotype features of TNBC, such as epithelial-to-mesenchymal transition (EMT) and angiogenesis (60, 61). MCs were shown to negatively correlate with therapy efficacy in inflammatory (I) breast carcinoma (11) and to be associated with no-pCR in a durvalumab/olaparib/paclitaxel trial enrolling patients with HER2-negative breast carcinoma, both HR-positive and TN (62). Moreover, by identifying a cancer-associated fibroblast signature predictive of OS, it was shown that a high-risk score correlated to increased MC infiltration in basal-like breast carcinomas (63).

MCs contain a large cargo of soluble factors whose release and composition could determine the activity of MCs in tumors. For instance, MC-related antitumor effect could be a consequence of ROS induction (64) or caused by release in the TME of cytotoxic mediators, as TNF (65). The expression of TNF is lower in cancer compared with non-cancer tissues, indicating that tumor cells could negatively affect MCs by reducing TNF and hence hindering their antitumor activities (66). The importance of MC-derived TNF is also supported by the observation that TNF levels are increased in responder or stable patients with lung cancer, compared with patients with progressive disease (66). In contrast, MC-derived proangiogenic factor VEGFA, whose abundance is positively correlated with microvessel density (17, 29), is linked to the protumoral effect of MCs (67). The expression of TNF and VEGFA in MCs is mutually exclusive and their levels vary across different cancer types. This observation could contribute to explain why MCs act in a different manner according to the type of cancer cells (66). MCs expressing a high VEGFA:TNF ratio appear to display a dominant proangiogenic effect in agreement with the observed correlation between MC abundance and vessel formation (68). MCs release numerous other angiogenic factors, including endothelin-1, GMCSF, CXCL8, and CCL2 (69). Barkaway and colleagues have recently described a new link between MCs and aged vasculature in mouse models (70). They found that MC quantity increases in aged organs and promotes tissue damage through the production of high levels of the inflammatory chemoattractant CXCL1, which stimulates the reverse transendothelial migration of neutrophils. This effect still needs to be investigated in the context of tumors, but could potentially impact cancer outcome by favoring the accumulation of MDSC.

The protumoral effect of MCs could also be mediated by the release of other factors such as TGFβ, which stimulates EMT, several proteases including matrix metalloproteinases (MMP; refs. 71, 72), for example, MMP9, which contribute to MC-mediated shaping of the extracellular matrix (ECM), as well as chymase and tryptase that modify pro-MMPs to their active forms (73). Furthermore, MCs are the major source of histamine, whose activity has been largely investigated in allergic reactions (74). However, there is increasing evidence showing that histamine is endowed also with immune modulating activities ultimately affecting cancer outcome. Upon MC activation, the endogenous production of histamine was shown to suppress the immune response and to contribute to breast carcinoma growth in mouse models (75). Moreover, the in vitro binding of histamine to H2 histamine receptors stimulated human monocyte-derived dendritic cells (DC) to synthesize IL10 (76) and, in patient-derived xenograft tumor models, prevented the production of IL12, which is responsible for Th1 expansion (77). This event causes DC-driven polarization of CD4⁺ T cells toward a Th2 phenotype (78). The protumoral effect of histamine has also been reported in patients with cholangiocarcinoma where it contributes to tumor growth (79). In this scenario, MC-mediated release of histamine increases cancer progression and angiogenesis by enhancing the expression of VEGF (23).

In breast carcinomas, MC-released IL4 has an ambiguous effect because of its dual role both in promoting cancer cell dissemination or induction of apoptosis of breast carcinoma cells. Specifically, an increase of IL4, which depends on HR status, and its positive correlation with resistance to apoptosis have been described supporting the idea that IL4 is a negative prognostic factor in patients with breast carcinoma (80). Conversely, it has been reported that IL4 inhibits growth and induces apoptosis of human breast carcinoma cell lines, such as MCF7 and MDA-MB-231 (81).

Several studies reported the capability of tumor-infiltrating MCs to shape the immune landscape (Fig. 1) either towards an antitumor or a protumor microenvironment (82), thus modulating the response to diverse therapeutic treatments. Because the composition of infiltrating immune cells differs among breast carcinoma subtypes, this may contribute to explain why MCs have a diverse impact in different breast carcinoma types. In particular, Dudeck and colleagues described the effect of MC TNF on T-cell priming. This mechanism could eventually influence their antitumor activity in the context of cancer. This work highlighted the potential of MC-derived TNF to amplify CD8⁺ DC functionality and linked MCs with T-cell and DC modulation (65). TNF is known to be beneficial for tumor shrinkage (83), to sensitize breast carcinoma cells in vitro and in vivo to chemotherapy and radiotherapy (84), and to play a critical role in mouse DC functionality and T-cell priming (65). These observations indicate that MCs promote a proinflammatory microenvironment through the release of TNF, affecting the efficacy of immunotherapy and vaccination strategies, at least in mouse models (65).

Collectively, these observations indicate that MCs support CD8⁺ T-cell activity, in disagreement with what suggested in inflammatory (I) breast carcinomas (11). In this context, MCs were shown to prevent treatment efficacy through their interaction with other immune subpopulations. More specifically, MCs, identified by tryptase staining, resulted more abundant in nonresponders where they were found in close proximity with CD8⁺ T cells, CD163⁺ macrophages, and tumor cells (11).

Several mouse studies described the engagement of MCs in the regulation of T-cell activities, including their recruitment and activation (85), as well as the impact on Tregs (86), which is bidirectional (87, 88). Nonetheless, the influence of MCs on T-cell functions is still controversial. In some studies, MCs have been shown to hinder the immune evasion mediated by Tregs in favor of the development of an effective antitumor immunity (14). In particular, it has been demonstrated that MCs are involved in the pathogenesis of diverse inflammatory conditions, for example, airway hyperreactivity and autoimmune encephalomyelitis, because they are able to counteract the immune suppression mediated by Tregs through the release of IL6, thus enabling their switch toward Th17 differentiation (14). In other works, it was described an opposite effect and MCs were shown to favor the immunosuppressive action of Tregs (86, 89). It has been reported that the stimulation with EGF-like growth factor amphiregulin (AREG) markedly enhanced the functions and efficiency of FOXP3+ Tregs, which express EGFR under inflammatory conditions (89). Notably, AREG is a predictive marker of poor therapy efficacy, particularly in patients with colorectal cancer bearing unmutated K-Ras (89–91), and it is highly upregulated upon MC activation (92). Therefore, MC-produced AREG may have a critical role for Treg functions and its release may represent a possible mechanism linking MCs and Tregs at the site of inflammation.

Other findings describing the cross-talk between MCs and Tregs support an effect of MCs on the response to anti-PD1 immune checkpoint inhibitor in murine melanoma models (30). A higher presence of MCs colocalizing with FOXP3+ Tregs was found in tumor tissue sections upon anti-PD-1 administration. By using the multi-targeted receptor TKI sunitinib, able to deplete MCs and Tregs, authors assessed a complete regression of tumors in combination with anti-PD-1 therapy. MC infiltration in tumors was also confirmed by CIBERSORT analysis of three independent RNA sequencing datasets of patients with melanoma treated with anti-PD-1 or immune checkpoint therapies. In another trial (93), MC presence was increased in anti-PD-1 nonresponder patients (30). These results show that MC infiltration is associated with the presence of FOXP3+ Tregs, along with the downmodulation of HLA-class I on tumor cells, lack of CD8⁺ T cells and subsequent ineffectiveness of the anti-PD-1 treatment.

Another mechanism by which MCs could promote immune evasion is constituted by their capability to interact with MDSC. MDSC are the key regulators of immunesurveillance escape given their capability to suppress T-cell responses (94). In colon carcinoma, MC presence increases the recruitment and activity of MDSC, supported by increased release of nitric oxide, which results in a proportional inhibition of T-cell proliferation and consequent tumor-induced tolerance (94). Concerning this aspect, it has been demonstrated that MC and MDSC cross-talk is mediated by CD40L-CD40 and this axis results in the suppression of tumor-specific T-cell response in prostate cancer models (12).

Tissue MCs can be detected in situ by metachromatic staining, such as toluidine blue, or by specific IHC to detect c-Kit (CD117) and tryptases (7). Alternatively, MC density can be inferred by gene expressing profile of whole tumors (95) exploiting deconvolution software as CIBERSORT (36). In situ detection of MCs displays the advantage that also the localization and the shape of MCs can be appreciated providing crucial information on their effect (96). In fact, several reports agree that MC predictive/prognostic value differs according to their localization: around tumor margins (41) or infiltrating the tumor mass (97). Moreover, the distance from other immune cell populations also affects the local immune microenvironment, possibly impacting on breast carcinoma response to therapy (11). MCs are endowed with immunomodulator activities in breast carcinoma and other solid tumors modifying the TME by either direct contact or secreting soluble factors. Therefore, the use of IHC or metachromatic staining allows to evaluate the spatial distribution of MCs, pending some limitations. In theory, the whole tumor should be analyzed because the distribution of MCs within the tumor is heterogeneous, more than one marker needs to be employed because no truly specific marker for MCs (e.g., c-Kit) is available and, finally, degranulated MCs are often difficult to detect.

On the other hand, MC signatures are increasingly used to quantify the presence of MCs in tumor tissues (98) and their activation state. CIBERSORT represents the most employed signature to estimate tumor-infiltrating immune populations and includes about 50 genes suitable to quantify the level of MC infiltration, also discriminating between resting and activated MCs (36). Resting MCs are generally less abundant in breast tumors compared with normal tissues, vice versa activated MCs are increased in breast carcinoma tissues. Nevertheless, these two MC statuses are associated with different cancer outcomes (38), sometimes even opposite, suggesting that the presence of MCs may not have a negative impact on tumors per se, but their activation is somehow linked to a more aggressive phenotype. This was first described in a pan-cancer analysis (37) and then applied specifically to breast carcinoma. Notably, the negative impact on OS and DFS of activated MCs is not observed in every breast carcinoma subtype, but it is significant in HER2-positive tumors (54). The same work supports the idea that activated MCs display even a positive effect on pCR in TNBC. As already mentioned, many genes, which are commonly exploited to identify MCs, are not really MC-specific and differently localized MCs are characterized by a diverse gene expression profile. Hence, a number of works tried to identify MC-specific genes also able to identify their particular activation states/subsets (99). As already mentioned, MC VEGFA:TNF ratio was shown to be prognostic (66). MCs represent the only cell type able to store preformed TNF in their granules (100), and hence display antitumor activities, while being capable of protumor effects via angiogenesis promotion (67, 101–105). Accordingly, different groups described the prognostic values of MC-related signatures (106) in diverse tumor types (12, 28, 107).

Because MCs represent key components of immune tumor infiltrate and have a crucial role in inflammation and angiogenesis (1), their targeting represents a possible strategy for therapeutic purposes (108). Several compounds for example, cromolyn sodium (109), nedocromil and lodoxamide are able to stabilize MCs hereby preventing their degranulation as well as the release of their mediators (110). It has been reported that the administration of cromolyn in TRAMP mice, a murine model of prostate cancer, increased the development of aggressive neuroendocrine areas, suggesting a protective effect of MCs in this tumor type (17). In mouse models of breast carcinoma, treatment with cromolyn induced an increase of blood clotting and hypoxia in subcutaneous 4T1 mammary adenocarcinoma cell line tumors supporting a role of MCs in the inhibition of hypoxia and blood clotting, which likely occurs via release of heparin, chymase, and tryptase (111). The inhibition of MCs by cromolyn sodium in cholangiocarcinoma determines the block of histamine release and, consequently, results in the reduction of tumor proliferation, angiogenesis and expression of mesenchymal markers (23).

In an attempt to inhibit the activity of MCs in angiogenesis, VEGFA was blocked through the employment of FDA-approved anti-angiogenic drugs that either target VEGF or its receptors (112). MC presence negatively affects the efficacy of antiangiogenic therapy (AAT) through the release of matrix-degrading granzyme B. By using a pancreatic tumor model, authors found that the absence of MC increased the antitumor efficacy of anti-VEGF-R2 antibody DC101, hence indicating that MCs hinder the sensitivity of tumors toward AAT. The mechanisms involved in this event are related to the expression of ECM-degrading proteases, specifically granzyme B, which is responsible for the release of proangiogenic factors, such as FGF-1 and GMCSF from the ECM (112). Another potential therapeutic approach to inhibit MCs in cancer is achievable through the pharmacologic targeting of the c-Kit receptor tyrosine kinase (113), which is essential for MC homeostasis, by the employment of TKI compounds including imatinib, dasatinib, and sunitinib, which inhibit the catalytic activity of both wild type and mutated, for example, D816V (114), c-Kit. The targeting of c-Kit/SCF interaction is also promising for the treatment of patients affected by cholangiocarcinoma because it results in the disruption of the cross-talk between MCs and cholangiocarcinoma cells with consequent reduction of tumor progression (23).

Initially neglected, MCs are progressively becoming crucial players in cancer, because increasing evidence supports their capability to affect outcome and therapy efficacy. Nonetheless, despite the many works that have been published in the last year, the ultimate role of MCs in tumors is far from being understood. Findings are characterized by apparently contradictory data, which actually are consequent of the plastic nature of MCs that are extremely sensitive to microenvironmental cues to which they suddenly respond. Hence, the effect of MCs cannot be limited to the dichotomy presence/absence, but it is caused, at least in breast carcinoma, by their activation and degranulation state, localization, secretion of cytokines and/or proteases, density, proximity to other immune and cancer cells. MCs could so represent an important tool to manipulate and predict cancer outcome, but, before they can be employed as prognostic/predictive markers or even as targets for novel therapeutic approaches, a deeper characterization of their biology and the identification of specific profiles associated to their activation and localization are still necessary.

No disclosures were reported.

D. Lecis and M.P. Colombo are supported by Associazione Italiana per la Ricerca sul Cancro (IG 2020 ID 24309 and IG 2020 IG 24363, respectively). M.T. Majorini is supported by a Fondazione Pezcoller-SIC fellowship.